Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -6.40 -12.7% 44.00 47.90 48.00 52.00 47.90 50.60 760,179 16:46:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -2.9 -1.0 - 113

Futura Medical Share Discussion Threads

Showing 20776 to 20795 of 21575 messages
Chat Pages: Latest  839  838  837  836  835  834  833  832  831  830  829  828  Older
DateSubjectAuthorDiscuss
31/3/2021
12:07
If they sign a deal they announce immediately,but nice try. You have spent hundreds of posts in a few days talking this down Always innuendo,the usual tactics.
j777j
31/3/2021
11:07
Anyway what we do know is.. "The Company has now received initial offers from a number of parties and believes the EU approval of MED3000 will assist the Company in its objective of delivering long-term, sustainable value through the licensing of MED3000." Also the Chinese have committed up to £6 million towards launching into China. They run a specialised health care fund and have put their money where their mouth is. I think I will add as newsflow is imminent on a number of fronts. ps Re Cannabidiol,you clearly havent done your research as those investors are experienced players.They set up a separate co specifically to JV with Fum. You are making it out as cloak and dagger when that is simply not the case.In any event they are working on a product which could become the key ingredient in all topically applied cannabidiol products.
j777j
31/3/2021
11:01
Yeah has some potential but they at very early days and needs a lot of capital to be invested. Like Kabey Pharma and CSD500 it does not inspire confidence when partners are unheard of and are only incorporating around the time the Futura deals are announced to the market https://cbderma-technology.com https://reportlet.co.uk/company/12133619/cbderma-technology-limited/ Also lot of risk in transdermal CBD https://news.bloomberglaw.com/esg/zynerba-experimental-cbd-company-sued-over-drug-trial-results
lbo
31/3/2021
10:34
Not forgetting the Cannabidiol product side. Why CBD Skin Care Could Beautify Your Life httPS://www.discovermagazine.com/health/why-cbd-skin-care-could-beautify-your-life
j777j
31/3/2021
10:32
Background on the author of the Discovery magazine article. https://en.m.wikipedia.org/wiki/Neuroskeptic https://www.discovermagazine.com/mind/am-i-an-unethical-pseudonym https://www.wired.com/2013/05/churchill-lincoln-too-can-help-you-whup-depression/
lbo
31/3/2021
10:23
One wonders if a competitor had it written. It is after all a US publication. Med3000 with a potential $1 billion peak sales,rapid speed of onset,no side effects and applied topically, is definitely a threat. Upsetting apple carts springs to mind. Players in a $5.7 billion pa market are probably rather agitated a tiny British upstart might disrupt their monopolies. Pzifer should be reminded Viagra was supposed to be a hypertension drug,they just got lucky.
j777j
31/3/2021
10:18
I agree with what the experts said. The efficacy does look “remarkable221; and is “of great interest to the medical community” I also “support”; “further clinical investigation” I also don’t disagree that extrapolating from the FM57 study which was not designed to study MED3000 but rather MED2005 then it can appear as if it “approaches the efficacy” So do Saffron gels in ED studies. I also agree as it doesn’t have any active drug it will have “significantly lower adverse events” and “lack of drug interactions”. So will any gel like using KY warming gel I also agree rubbing a gel on your partner may have faster arousal results then a taking an oral PDEi. So will using any gel like KY warming gel I also agree "All formulations tested in FM57, including MED3000, have demonstrated positive and statistically significant efficacy results against baseline data together with excellent safety profile” the key word here is they ALL had an effect in this study. I also agree due to whats now being claimed it is indeed of “high interest”. Placebo effects always have been and the ethics behind if doctors should use them. I also agree "Erectile dysfunction often becomes a barrier to spontaneity and intimacy in a relationship, which harms both the man and his partner over time” A product -such as MED3000 - that can be applied as part of foreplay could help to break down the barriers that have proved so difficult to overcome with existing treatments” But again as they say themselves so could any gel like MED3000 eg KY warming gel.
lbo
31/3/2021
09:41
Bought a few more at 48.9p
volsung
31/3/2021
09:15
the thread with charts is better
cordwainer
31/3/2021
08:38
https://www.discovermagazine.com/health/the-erection-of-a-placebo
lbo
30/3/2021
18:28
They have basically been saying the same thing regarding commercialisation on MED for years but no real distribution partner has signed. (The China deal was structured as an option/financial instrument not a real distribution deal) 11 September 2019 “Discussions continue with a number of interested commercial partners for the out-licensing of MED2005” 14 July 2020 “Commercial partnering interest in MED3000, where received, has strongly focused on its potential” 10th August 2020 “Futura has now appointed specialised corporate advisers with international experience to facilitate commercial discussions with potential licensing and marketing partners”
lbo
30/3/2021
18:21
Or it won’t because of the Patent issues? Read the 19th March wording on the Commercialisation update closely. Why will EU approval only “assist”? Why are the offers only “initial”;? Could it be they are highly conditional on the exact marketing claims allowed by the Regulators? Could they be conditional on consumer user studies being also required by partners before launch? Its what happened with CSD500. Also the CE mark will be awarded to Futura? The manufacturing dossier will need to be submitted and be approved by each distribution partner in each region before they can launch in any region. Also happened with CSD500. These all cause delays and costs to any partner. Probably why they emphasising the “long term” “In conjunction with the regulatory processes, Futura has been working with retained specialised corporate advisers on active commercial discussions with potential licensing and marketing partners” (As it has been saying for years) “Following the Company's recent announcement of a Joint Collaboration agreement for the China and the South East Asia region, partnering discussions for other countries continue in line with the agreed process being managed by Futura's corporate advisers. The Company has now received initial offers from a number of parties and believes the EU approval of MED3000 will assist the Company in its objective of delivering long-term, sustainable value through the licensing of MED3000”
lbo
30/3/2021
15:53
"Futura's commercialisation collaborations." Note the plural.I guess another deal can be announced anytime.
j777j
30/3/2021
14:08
News today; hTTps://www.dailymail.co.uk/news/article-9418125/Covid-19-Men-contract-coronavirus-THREE-TIMES-risk-developing-erectile-dysfunction.html Men who contract Covid-19 treble their risk of developing erectile dysfunction, according to new research.
pdt
30/3/2021
10:37
As said previously LBO - 25 Mar 2021 - 08:59:01 - 9128 of 9245 Sadly that was not the case with CSD500 after it got its CE Mark too. The licensing and distribution deals were signed on it too but it never generated any Royalties for Futura. And the reason is simple and was seen with CSD500 in the Netherlands with BizzyDiamond, Kabey Pharma in the Middle East, Portugal and F Lima SA, Nordic countries and RFSU, South East Europe and Milsing, South Korea and Kwang Dong Pharmaceuticals. Same issue arises now as Futura will be entitled to 50% of regional profits from the commercialisation of MED3000. That profit is net of the set up, marketing and distribution costs which are massive costs especially for small distributors. Even the large brands distributors like Reckitt, Church and Dwight and Ansell who all had signed deals realised it and walked away and decided the product didn’t have enough differentiation or potential even for their large established brands like Durex, Trojan, Lifestyles and Jissbon to risk investing the sums needed to get consumers to buy it.
lbo
29/3/2021
16:01
Bought a few more for 53.35p
volsung
29/3/2021
15:54
personally I think the big pharmas will wait for the patent. But if they do wait and the patent is extended until 2039 it will cost them a lot more to buy FUM, which suits me fine For me, FUM do not have a great track record and have a few failed products. I cannot believe we've still not heard anything about TPR100. I've even emailed them about it and nothing. But they have finally got a product and the recent spike in the share price has made me a lot of money and I will be holding for FUM to make me even more money.....
keifer derrin
29/3/2021
15:32
Sure! But it seems odd no Pharma is coming forward or shown any interest in MED 3000 in Europe whilst final certification of EU is around the corner ! e.g. about 6-8 weeks away
sightwatcher
29/3/2021
15:10
The other thing nobody on here has mentioned is Fum has become a SETS stock as of today hence the jumping around in the share price
j777j
29/3/2021
15:06
Actually up to £ 2 million plus they are paying up to a further £4 million to bring Med3000 into the Chinese market.I have done some research and the fact they already have EU approval will greatly speed up the process.In addition to that the company has told us they have received initial offers from a number of different countries. Plenty of newsflow around the corner.
j777j
Chat Pages: Latest  839  838  837  836  835  834  833  832  831  830  829  828  Older
ADVFN Advertorial
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210517 04:31:19